ISOPLEXIS CORPORATION Inactive Instrument
IsoPlexis Corporation Stock
Equities
ISO
US4650051067
Advanced Medical Equipment & Technology
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 14-12-31 |
John H. Leamon
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Anthony Catalano
COO | Chief Operating Officer | - | 21-11-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Scott Chaplin
BRD | Director/Board Member | 56 | 23-03-20 |
James McClaskey
BRD | Director/Board Member | 46 | 23-03-20 |
IsoPlexis Corporation is a life sciences company. The Company is engaged in building solutions to develop curative medicines and personalized therapeutics. The Company's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The Company's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. The Company's IsoSpeak software provides automated data analysis and accelerated insights with a push-button user interface.
| 1st Jan change | Capi. | |
|---|---|---|
| +4.16% | 32.45B | |
| +12.62% | 7.26B | |
| +20.83% | 3.84B | |
| -11.41% | 3.43B | |
| -27.11% | 1.31B | |
| -34.31% | 1.11B | |
| +4.25% | 919M | |
| -23.45% | 856M | |
| -38.17% | 840M |
